Physician profile
James P Wallace
NPI 1487741146
$15,162.59
in general payments reported to CMS, 2019-2025
60 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $1,737 · 2021: $3,247 · 2022: $2,505 · 2023: $1,968 · 2024: $1,987 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,003.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.04 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,103.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $985.72 | 2019-2025 | |
| Lilly USA, LLC | $973.14 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $917.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $780.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $654.40 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $598.31 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $595.75 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $588.04 | 2019-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $585.16 | 2019-2025 | Freestyle Libre 3 |
| Forte Bio-Pharma LLC | $580.86 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Janssen Pharmaceuticals, INC | $552.08 | 2019-2024 | Xarelto |
| Ironwood Pharmaceuticals, INC | $419.13 | 2021-2025 | Linzess |
| Sunovion Pharmaceuticals INC. | $405.44 | 2019-2022 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $384.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.10 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Allergan, INC. | $260.79 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.01 | 2019-2022 | |
| Corcept Therapeutics | $244.77 | 2021-2025 | Korlym |
| Astellas Pharma US INC | $194.24 | 2019-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $185.28 | 2019-2022 | |
| Mylan Specialty L.P. | $185.00 | 2019-2024 | Yupelri |
| Sumitomo Pharma America, INC. | $178.90 | 2023-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $159.14 | 2021-2025 | Nexletol |
| Scilex Pharmaceuticals INC. | $147.72 | 2024-2025 | |
| Daiichi Sankyo INC. | $136.12 | 2021-2025 | Injectafer |
| Exact Sciences Corporation | $129.92 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $112.00 | 2024-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $108.35 | 2019-2024 | Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.81 | 2025 | Caplyta |
| Novo Nordisk INC | $76.61 | 2019-2024 | Tresiba, Rybelsus, Ozempic |
| Vifor Pharma, INC. | $57.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $56.76 | 2023-2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $51.79 | 2021-2022 | |
| Seqirus USA INC | $48.74 | 2025 | Flucelvax, Fluad |
| Eisai INC. | $42.56 | 2021 | |
| Almatica Pharma LLC | $32.56 | 2021 | |
| Axsome Therapeutics, INC. | $30.99 | 2025 | Auvelity, Symbravo |
| Array Biopharma INC | $28.75 | 2025 | Lorbrena |
| Phathom Pharmaceuticals, INC. | $28.25 | 2025 | Voquezna |
| Upsher-Smith Laboratories LLC | $28.07 | 2020 | |
| Boston Scientific Corporation | $28.07 | 2019-2023 | Watchman Flx |
| Gilead Sciences, INC. | $25.81 | 2025 | Trodelvy |
| Advanced Respiratory, INC | $23.47 | 2021 | |
| Ardelyx, INC. | $21.59 | 2024 | Ibsrela |
| Paratek Pharmaceuticals, INC. | $20.11 | 2023 | Nuzyra |
| Biohaven Pharmaceuticals, INC. | $19.72 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.44 | 2023 | Gvoke Hypopen |
| Lexicon Pharmaceuticals, INC. | $18.08 | 2023 | Inpefa |
| Aimmune Therapeutics, INC. | $17.00 | 2025 | Zenpep |
| Medicure Pharma INC. | $16.72 | 2021 | |
| Genentech USA, INC. | $15.60 | 2020 | |
| Avion Pharmaceuticals | $14.56 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.30 | 2022 | |
| The Binding Site INC. | $14.23 | 2024 | Freelite |
| Edwards Lifesciences Corporation | $13.48 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ultragenyx Pharmaceutical INC. | $11.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.42 | 2020 | |
| Cvrx, INC. | $10.22 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.